Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
63 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Cough - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Cough - Pipeline Review, H2 2014', provides an overview of the Cough's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cough, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cough and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Cough - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cough and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cough products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cough pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cough - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cough pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Cough Overview 8 Therapeutics Development 9 Pipeline Products for Cough - Overview 9 Pipeline Products for Cough - Comparative Analysis 10 Cough - Therapeutics under Development by Companies 11 Cough - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Cough - Products under Development by Companies 16 Cough - Companies Involved in Therapeutics Development 17 Boehringer Ingelheim GmbH 17 Sanofi 18 Takeda Pharmaceutical Company Limited 19 Daewoong Pharmaceutical Co., Ltd. 20 Ahn-Gook Pharmaceutical Co., Ltd. 21 Hyundai Pharmaceutical Co., Ltd. 22 Hydra Biosciences, Inc. 23 Tris Pharma, Inc. 24 Neos Therapeutics, Inc. 25 AUS Bio Limited 26 Hanmi Pharmaceuticals, Co. Ltd. 27 Cough - Therapeutics Assessment 28 Assessment by Monotherapy Products 28 Assessment by Combination Products 29 Assessment by Target 30 Assessment by Mechanism of Action 32 Assessment by Route of Administration 34 Assessment by Molecule Type 36 Drug Profiles 38 AG-1321001 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 CCP-01 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 tetanus toxoid + reduced diphtheria toxoid + acellular pertussis vaccine adsorbed - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 TAK-361S - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 AG-1321001-SY - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 ambroxol - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 (ambroxol + levodropropizine) - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 HOB-048 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 CCP-07 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 HC-030031 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 AGPPC-709 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 MD-990 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 CCP-06 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 CCP-05 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 CCP-08 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Small Molecule for Cough and Cold - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 DWJ-1340 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Cough - Recent Pipeline Updates 55 Cough - Dormant Projects 56 Cough - Discontinued Products 57 Cough - Product Development Milestones 58 Featured News & Press Releases 58 Jul 22, 2014: Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 58 Jun 30, 2014: Submission of Tuzistra XR (CCP-01) NDA to FDA 58 Feb 24, 2014: Vernalis Announces Successful Completion of Second Pivotal Bioavailability Study with First Cough Cold Product, CCP-01 58 Dec 11, 2013: Ario Pharma to Develop Novel Therapeutics for Respiratory Indications 59 Jun 28, 2013: TESARO Announces Presentation of Rolapitant Pharmacokinetic Data at the MASCC/ISOO International Symposium 59 Mar 06, 2013: Vernalis's First Product In Cough Cold Pipeline Achieves Proof-of-concept 60 Apr 11, 2012: Cerecor Announces Clearance Of IND For FP01 60 Jan 06, 2012: Tris Pharma Announces US Patent Grant Covering Platform Technology 60 Appendix 62 Methodology 62 Coverage 62 Secondary Research 62 Primary Research 62 Expert Panel Validation 62 Contact Us 63 Disclaimer 63
List of Tables Number of Products under Development for Cough, H2 2014 9 Number of Products under Development for Cough - Comparative Analysis, H2 2014 10 Number of Products under Development by Companies, H2 2014 12 Comparative Analysis by Late Stage Development, H2 2014 13 Comparative Analysis by Clinical Stage Development, H2 2014 14 Comparative Analysis by Early Stage Development, H2 2014 15 Products under Development by Companies, H2 2014 16 Cough - Pipeline by Boehringer Ingelheim GmbH, H2 2014 17 Cough - Pipeline by Sanofi, H2 2014 18 Cough - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 19 Cough - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2014 20 Cough - Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H2 2014 21 Cough - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2014 22 Cough - Pipeline by Hydra Biosciences, Inc., H2 2014 23 Cough - Pipeline by Tris Pharma, Inc., H2 2014 24 Cough - Pipeline by Neos Therapeutics, Inc., H2 2014 25 Cough - Pipeline by AUS Bio Limited, H2 2014 26 Cough - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2014 27 Assessment by Monotherapy Products, H2 2014 28 Assessment by Combination Products, H2 2014 29 Number of Products by Stage and Target, H2 2014 31 Number of Products by Stage and Mechanism of Action, H2 2014 33 Number of Products by Stage and Route of Administration, H2 2014 35 Number of Products by Stage and Molecule Type, H2 2014 37 Cough Therapeutics - Recent Pipeline Updates, H2 2014 55 Cough - Dormant Projects, H2 2014 56 Cough - Discontinued Products, H2 2014 57
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
